Impact of CD133 (AC133) and CD90 expression analysis for acute leukemia immunophenotyping

Robert-Rossle-Clinic, Charite, Humboldt University of Berlin, Lindenberger Weg 80, 13125 Berlin, Germany. wuchter@rrk-berlin.de BACKGROUND AND OBJECTIVES: AC133 is a novel monoclonal antibody (Moab) reacting with a population of immature/primitive or granulo-monocytic committed CD34+ve cells. Up to...

Full description

Saved in:
Bibliographic Details
Published in:Haematologica (Roma) 2001-02, Vol.86 (2), p.154-161
Main Authors: Wuchter, C, Ratei, R, Spahn, G, Schoch, C, Harbott, J, Schnittger, S, Haferlach, T, Creutzig, U, Sperling, C, Karawajew, L, Ludwig, WD
Format: Article
Language:English
Subjects:
AC133 Antigen
Acute Disease
Adolescent
Adult
Aged
Aged, 80 and over
Antibodies, Monoclonal
Antigens, CD
Antigens, CD34 - metabolism
Biological and medical sciences
Cell Lineage - immunology
Child
Child, Preschool
Glycoproteins - immunology
Glycoproteins - metabolism
Hematologic and hematopoietic diseases
Hematopoietic Stem Cells - immunology
Humans
Immunophenotyping
Infant
Leukemia - blood
Leukemia - immunology
Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis
Medical sciences
Middle Aged
Peptides - immunology
Peptides - metabolism
Thy-1 Antigens - metabolism
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Robert-Rossle-Clinic, Charite, Humboldt University of Berlin, Lindenberger Weg 80, 13125 Berlin, Germany. wuchter@rrk-berlin.de BACKGROUND AND OBJECTIVES: AC133 is a novel monoclonal antibody (Moab) reacting with a population of immature/primitive or granulo-monocytic committed CD34+ve cells. Up to now, only few studies with small numbers of cases have examined AC133 (recently designated CD133) expression in acute leukemia. To determine the value of this Moab for acute leukemia immunophenotyping, we investigated a large series of leukemic cell samples for their reactivity with Moab AC133. DESIGN AND METHODS. A total of 298 cell samples from patients with de novo acute myeloid leukemia (AML) (n=142), acute lymphoblastic leukemia (ALL) (n=119), CD34+ve biphenotypic acute leukemia (n=13), and CD34+ve CML blast crisis (=BC; 21 myeloid BC/3 lymphoid BC) were investigated by flow cytometry for Moab AC133 reactivity.CD133 expression was compared with CD90(Thy-1) expression, another CD34-associated antigen. RESULTS: Fifteen (5%) samples expressed CD90, whereas 114 (38%) samples were positive for Moab AC133 (20% cut-off level). No significant differences in CD133 and CD90 expression levels between AML and ALL were observed. In AML, but not ALL, CD133 was more often expressed in CD34+ve cases than in CD34-ve ones (p
ISSN:0390-6078
1592-8721